Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

Uveal Melanoma

Salivary Gland Neoplasms

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Pancreatic Neoplasms

Nasopharyngeal Carcinoma

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

Head and Neck Neoplasms

Uveal Melanoma, Melanoma

Carcinoma, Hepatocellular

Prostatic Neoplasms

Carcinoma, Non-Small-Cell Lung

Metastatic Microsatellite Stable Colorectal Cancer

Carcinoma, Renal Cell

Carcinoma, Transitional Cell, Neoplasm Metastasis

Rectal Neoplasms

Uveal Melanoma

Carcinoma, Renal Cell

Neoplasms, Unknown Primary

Squamous-Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Melanoma

Stomach Neoplasms

Carcinoma, Non-Small-Cell Lung

Bone Neoplasms, Chondrosarcoma, Sarcoma, Osteosarcoma, Gastrointestinal Stromal Tumors, Desmoplastic Small Round Cell Tumor

Squamous Cell Carcinoma of Head and Neck, Hypoxia, Melanoma, Pancreatic Neoplasms, Prostatic Neoplasms

Melanoma, Neoplastic Cells, Circulating, Neoplasm Metastasis

Brain Neoplasms

Clinical Trials

Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma

BreastImmune03

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

ANZUP2001

Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer

OpACIN-neo

Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

ROME

RAR-Immune

IMSTAR-HN

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

PRIME-HCC

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Luscid

Nivolumab+Ipilimumab+RT in MSS mCRC

OpACIN

CHARLI

UNISoN

TITAN-TCC

Study to Nivolumab Following Preoperative Chemoradiotherapy

Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.

CheCUP

SQUINT

NIBIT-ML1

da VINci

SEQUENCE

A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

SART

NIBIT-M4

NIBIT-M2